Krystal Biotech, Inc. (KRYS) — SEC Filings
Krystal Biotech, Inc. (KRYS) — 38 SEC filings. Latest: 8-K (May 4, 2026). Includes 16 8-K, 9 SC 13G/A, 7 10-Q.
View Krystal Biotech, Inc. on SEC EDGAR
Overview
Krystal Biotech, Inc. (KRYS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: Krystal Biotech, Inc. filed an 8-K on December 23, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 2 bullish, 36 neutral. The dominant filing sentiment for Krystal Biotech, Inc. is neutral.
Filing Type Overview
Krystal Biotech, Inc. (KRYS) has filed 16 8-K, 7 10-Q, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of KRYS's 25 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $97.8M |
| Net Income | $79.365M |
| EPS | $2.66 |
| Debt-to-Equity | 0.09 |
| Cash Position | $731.1M |
| Operating Margin | 42.3% |
| Total Assets | $1.24B |
| Total Debt | $102.2M |
Key Executives
- Abigail P. Johnson
Industry Context
Krystal Biotech operates in the highly competitive and innovative biotechnology sector, focusing on gene therapies for rare diseases. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Success hinges on scientific breakthroughs, effective clinical trials, and successful commercialization strategies in niche markets.
Top Tags
disclosure (7) · regulation-fd (6) · Biotechnology (4) · 10-Q (4) · biotech (4) · sec-filing (4) · corporate-governance (3) · SEC Filing (3) · regulatory-filing (3) · Krystal Biotech (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product revenue, net (Q3 2025) | $97.8M | Increased from $83.8M in Q3 2024, a 16.7% increase |
| Product revenue, net (9 months ended Sep 30, 2025) | $282.0M | Increased from $199.4M in 2024, a 41.4% increase |
| Net income (Q3 2025) | $79.365M | Increased from $27.180M in Q3 2024 |
| Net income (9 months ended Sep 30, 2025) | $153.431M | Increased from $43.680M in 2024 |
| Cash, cash equivalents, and short-term investments | $731.1M | As of September 30, 2025, sufficient for at least 12 months of operations |
| Accumulated deficit | $27.2M | As of September 30, 2025, significantly reduced from $180.668M at Dec 31, 2024 |
| Total operating expenses (Q3 2025) | $56.426M | Decreased from $61.369M in Q3 2024 |
| Litigation settlement expense | $12.5M | Incurred in Q3 2024, not present in Q3 2025 |
| Q2 2025 Product Revenue | $55.2M | Significant increase from $0 in Q2 2024, indicating successful commercialization. |
| H1 2025 Product Revenue | $98.5M | Strong half-year revenue, demonstrating market penetration. |
| Q2 2025 Net Loss | -$15.8M | Narrowed from -$45.1M in Q2 2024, showing improved financial performance. |
| Cash and Equivalents | $520.3M | Robust liquidity as of June 30, 2025, supporting ongoing operations. |
| Q2 2025 R&D Expenses | $25.3M | Decrease from $28.7M in Q2 2024, reflecting a shift in focus post-launch. |
| Q2 2025 SG&A Expenses | $38.1M | Increased from $18.5M in Q2 2024, driven by commercialization efforts. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the fiscal quarter covered by the report. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, but potentially slightly adjusted, stake in Krystal Biotech, Inc. over the next year.","entity":"FMR LLC","targetDate":"2025-02-12","confidence":"medium"}
- {"claim":"FMR LLC will maintain a significant, albeit potentially fluctuating, stake in Krystal Biotech, Inc.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Krystal Biotech, Inc. (KRYS)?
Krystal Biotech, Inc. has 38 recent SEC filings from Jan 2024 to May 2026, including 16 8-K, 9 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KRYS filings?
Across 38 filings, the sentiment breakdown is: 2 bullish, 36 neutral. The dominant sentiment is neutral.
Where can I find Krystal Biotech, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Krystal Biotech, Inc. (KRYS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Krystal Biotech, Inc.?
Key financial highlights from Krystal Biotech, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KRYS?
The investment thesis for KRYS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Krystal Biotech, Inc.?
Key executives identified across Krystal Biotech, Inc.'s filings include Abigail P. Johnson.
What are the main risk factors for Krystal Biotech, Inc. stock?
Of KRYS's 25 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Krystal Biotech, Inc.?
Recent forward-looking statements from Krystal Biotech, Inc. include guidance on {"claim":"FMR LLC will maintain a significant, but potentially slightly adjusted, stake in Krystal Biotech, Inc. over th and 1 other predictions.